This site is intended for US healthcare professionals

This site is intended for US healthcare professionals

Partner with us

The details matter

Who to Contact

Service/Support Hours of Operation Phone Email
Medical Affairs / Adverse Event Reporting

9:00 AM – 5:00 PM EST
Monday-Friday

 P: 877-993-8779F: +1-609-559-0699
Customer Service

8:30 AM – 5:00 PM EST
Monday-Friday

 P: 877-993-8779F: +1-877-993-9055
Medical Affairs / Adverse Event Reporting
Hours of Operation Phone Email

9:00 AM – 5:00 PM EST
Monday-Friday

 P: 877-993-8779F: +1-609-559-0699
Customer Service
Hours of Operation Phone Email

8:30 AM – 5:00 PM EST
Monday-Friday

 P: 877-993-8779F: +1-877-993-9055

Request a NUFYMCO Representative

Complete the form below to be contacted by a Zydus representative for NUFYMCO information and/or support

    I would like to be contacted by:

    By clicking "Submit", you confirm that you are a US healthcare professional and agree to be contacted by a representative of Zydus Pharmaceuticals, Inc. In addition, you agree to receive information about Zydus Pharmaceuticals, Inc, including information about any of its current or future products or product candidates or disease state information and you may opt out at any time, and you acknowledge that you have read and agree to Zydus Pharmaceuticals, Inc's Privacy Policy and Terms of Use. All personal information will be kept confidential and will not be shared with any parties other than Zydus Pharmaceuticals, Inc and its business partners.

    Not actual patients.

    Regional NUFYMCO Support

    Selected State

    State Representative

    State representative
    email address

    Field Reimbursement Manager

    Field Reimbursement Manager
    email address

    Medicare MAC Coverage

    Mac region

    Loading map…

    Zydus and its agents make no guarantee regarding reimbursement for any service or item. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. For eligibility requirements, please contact a patient assistance specialist.

    To report adverse events or product complaints please email medicalaffairs@zydususa.com,
    call 877-993-8779, or fax +1-609-559-0699 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    IMPORTANT SAFETY INFORMATION AND INDICATIONS

    CONTRAINDICATIONS

    NUFYMCO is contraindicated in patients with:

    • Ocular or periocular infections
    • Known hypersensitivity to ranibizumab products or any of the excipients in NUFYMCO. Hypersensitivity reactions may manifest as severe intraocular inflammation.

    WARNINGS AND PRECAUTIONS

    Endophthalmitis and Retinal Detachments

    Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering NUFYMCO. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

    Increases in Intraocular Pressure

    Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with NUFYMCO and manage appropriately.

    Thromboembolic Events

    Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

    Neovascular (Wet) Age-Related Macular Degeneration

    The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3.
    In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg ranibizumab compared to 1.1% (5 of 435) in patients in the control arms [odds ratio 2.2 (95% confidence interval (0.8-7.1)].

    Macular Edema Following Retinal Vein Occlusion

    The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms.

    Diabetic Macular Edema and Diabetic Retinopathy

    In a pooled analysis of Studies D-1 and D-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg ranibizumab, 5.6% (14 of 250) with 0.3 mg ranibizumab, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg ranibizumab, 1.2% (3 of 250) with 0.3 mg ranibizumab, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg ranibizumab and 10.8% (27 of 250) with 0.3 mg ranibizumab; the stroke rate was 4.8% (12 of 249) with 0.5 mg ranibizumab and 2.0% (5 of 250) with 0.3 mg ranibizumab.

    Fatal Events in Patients with DME and DR at Baseline

    A pooled analysis of Studies D-1 and D-2 showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg ranibizumab, in 2.8% (7 of 250) of patients treated with 0.3 mg ranibizumab, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg ranibizumab and in 4.4% (11 of 250) of patients treated with 0.3 mg ranibizumab. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

    Retinal Vasculitis with or without Occlusion

    Retinal vasculitis with or without occlusion, typically in the presence of preexisting intraocular inflammation or post-treatment with other intravitreal agents, have been reported with the use of ranibizumab products. Discontinue treatment with NUFYMCO in patients who develop these events. Patients should be instructed to report any change in vision without delay.

    ADVERSE REACTIONS

    Injection Procedure

    Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

    Clinical Trials Experience

    In clinical trials, the most common ocular adverse reactions included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

    Immunogenicity

    As with all therapeutic proteins, there is the potential for an immune response in patients treated with ranibizumab products. The pre-treatment incidence of immunoreactivity to ranibizumab was 0%-5% across treatment groups. After monthly dosing with ranibizumab for 6 to 24 months, antibodies to ranibizumab were detected in approximately 1%-9% of patients. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time.

    Postmarketing Experience

    The following adverse reaction has been identified during post-approval use of ranibizumab products. Because this reaction was reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

    • Ocular: Tear of retinal pigment epithelium among patients with neovascular AMD

    INDICATIONS AND USAGE

    NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

    • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    • Macular Edema Following Retinal Vein Occlusion (RVO)
    • Diabetic Macular Edema (DME)
    • Diabetic Retinopathy (DR)
    • Myopic Choroidal Neovascularization (mCNV)

    To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

    Please see full Prescribing Information for NUFYMCO.

    References

    1. NUFYMCOTM (ranibizumab-leyk) Prescribing Information. Zydus Pharmaceuticals (USA) Inc.; revised June 2026.
    2. LUCENTIS® (ranibizumab injection) [prescribing information]. Genentech, Inc.; revised February 2024.
    3. U.S. Food and Drug Administration. Purple Book: Database of Licensed Biological Products. Accessed August 13, 2026. https://purplebooksearch.fda.gov/index.cfm?blaNo=761473&event=productdetails
    4. U.S. Food and Drug Administration. Considerations in Demonstrating Interchangeability With a Reference Product: Guidance for Industry. Published May 2019. Accessed August 13, 2026. https://www.fda.gov/media/124907/download
    5. Holz FG, Oleksy P, Ricci F, et al; for the COLUMBUS-AMD Study Group. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54-63. doi:10.1016/j.ophtha.2021.04.031.
    6. Data on File. Zydus Pharmaceuticals (USA) Inc.
    7. Centers for Medicare & Medicaid Services. July 2026 Alpha-Numeric HCPCS File. Updated June 17, 2026. Accessed August 13, 2026. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update

    You are now leaving the Nufymco website

    You are being directed to a third-party website. Zydus does not control or endorse the content of the third-party website and is not responsible for its content.

    Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration

    Frank G. Holz, MD, Piotr Oleksy, MD, Federico Ricci, MD, Joachim Kiefer, PhD, Steffen Schmitz-Valckenberg, MD
    American Academy of Ophthalmology. January 2022

    Ok